Soluble (pro)renin receptor treats metabolic syndrome in mice with diet-induced obesity via interaction with PPARγ
Open Access
- 9 April 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
The therapies available for management of obesity and associated conditions are limited, because they are often directed toward an individual component of metabolic syndrome and are associated with adverse effects. Here, we report the multifaceted therapeutic potential of histidine-tagged recombinant soluble (pro)renin receptor (sPRR), termed sPRR-His, in a mouse model of diet-induced obesity (DIO). In the DIO model, 2-week administration of sPRR-His lowered body weight and remarkably improved multiple metabolic parameters in the absence of fluid retention. Conversely, inhibition of endogenous sPRR production by PF429242 induced diabetes and insulin resistance, both of which were reversed by the sPRR-His supplement. At the cellular level, sPRR-His enhanced insulin-induced increases in glucose uptake via upregulation of phosphorylated AKT and protein abundance of glucose transporter 4. Promoter and gene expression analysis revealed PRR as a direct target gene of PPARγ. Adipocyte-specific PPARγ deletion induced severe diabetes and insulin resistance associated with reduced adipose PRR expression and circulating sPRR. The sPRR-His supplement in the null mice nearly normalized blood glucose and insulin levels. Additionally, sPRR-His treatment suppressed DIO-induced renal sodium-glucose cotransporter-2 (SGLT2) expression. Overall, sPRR-His exhibits a therapeutic potential in management of metabolic syndrome via interaction with PPARγ.This publication has 57 references indexed in Scilit:
- Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular MechanismsPPAR Research, 2013
- Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysisBiomedical Reports, 2012
- Thiazolidinediones and PPARγ agonists: time for a reassessmentTrends in Endocrinology & Metabolism, 2012
- The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular spaceHypertension Research, 2011
- Soluble Form of the (Pro)Renin Receptor Generated by Intracellular Cleavage by Furin Is Secreted in PlasmaHypertension, 2009
- Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2008
- PPARs and the kidney in metabolic syndromeAmerican Journal of Physiology-Renal Physiology, 2008
- Safety issues and prospects for future generations of PPAR modulatorsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Diabetes and Vascular Disease Research, 2005
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002